Advertisement

Topics

Latest "Fraunhofer ITEM" News Stories

02:16 EST 17th December 2018 | BioPortfolio

Here are the most relevant search results for "Fraunhofer ITEM" found in our extensive news archives from over 250 global news sources.

More Information about Fraunhofer ITEM on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Fraunhofer ITEM for you to read. Along with our medical data and news we also list Fraunhofer ITEM Clinical Trials, which are updated daily. BioPortfolio also has a large database of Fraunhofer ITEM Companies for you to search.

Showing "Fraunhofer ITEM" News Articles 1–25 of 226

Saturday 15th December 2018

$LLY to Acquire Pre-Clinical Pain Program from Hydra Biosciences http://lilly.mediaroom.com/index.php?s=9042&item=137853 … http://www.hydrabiosciences.com/programs_ion_pipeline.htm …

$LLY to Acquire Pre-Clinical Pain Program from Hydra Biosciences http://lilly.mediaroom.com/index.php?s=9042&item=137853 … http://www.hydrabiosciences.com/programs_ion_pipeline.htm …


Friday 14th December 2018

Most Popular NEJM Group Feature: Bacterial Vaginosis Review

Here's the most clicked-on item we featured from NEJM Group this week, in case you missed it the first time around: NEJM Primary Care...

Thursday 13th December 2018

Akebia Therapeutics and Keryx Biopharmaceuticals Complete Merger, Creating Fully Integrated Renal Company

Akebia Therapeutics, Inc. (Nasdaq:AKBA) and Keryx Biopharmaceuticals, Inc. today announced the successful completion of their previously announced merger. "We are very pleased to announce the completion of our merger with Keryx to create a fully integrated renal company that has the potential to set new standards of care for patients with kid...


Wednesday 12th December 2018

Zoetis Announces Authorization of $2 Billion Share Repurchase Program

Company Also Declares First Quarter 2019 Dividend; Board Approves 30% Payment Increase Zoetis Inc. (NYSE: ZTS) today announced that its Board of Directors has authorized a $2 billion multi-year share repurchase program as part of its long-term capital allocation plans. The shares are expected to be repurchased over a multi-year period, and the program ...

CORRECTING and REPLACING Ritual Expands Corporate Program, Launches Ritual For Business in U.S.

Building on the Success of its Canadian Corporate Program, Ritual Brings Food Perks to U.S. and Helps Businesses Encourage Healthier Lunch Choices Third paragraph, fourth sentence of release should read: We are also proud that Ritual for Business...(instead of We are also proud that Ritual for Work...). The corrected release reads: ...

Ritual Expands Corporate Program, Launches Ritual For Business in U.S.

Building on the Success of its Canadian Corporate Program, Ritual Brings Food Perks to U.S. and Helps Businesses Encourage Healthier Lunch Choices Order ahead app Ritual announced today the launch of Ritual for Business in the U.S., bringing wellness-focused, incentivized perks and sustainable food options to businesses of all sizes. ...

Holidays Can be Stressful for Children with Autism and Their Families

Holidays are a time of joy for many people, but families with children and teens on the autism spectrum can find the holidays challenging. Disrupted schedules and broken routines can make even simple things difficult for children with autism spectrum disorder (ASD), making it crucial for their families and them to be prepared. “The holiday seaso...

AC Immune and Lilly Announce License and Collaboration Agreement

Multi-year agreement focuses on Morphomer tau aggregation inhibitors, for the potential treatment of Alzheimer’s disease and other neurodegenerative diseases. AC Immune to receive an initial upfront payment of CHF80 million and will be eligible for CHF60 million in potential near-term development milestones, up to approxim...

Tuesday 11th December 2018

Walgreens Boots Alliance Announces Transfer of Listing of Debt Securities to Nasdaq

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced it will be transferring the securities exchange listing for its 2.125% Senior Notes due 2026, 2.875% Senior Notes due 2020 and 3.600% Senior Notes due 2025 from the New York Stock Exchange to the Nasdaq Bond Exchange effective December 21, 2018 after market close. The debt securities are expected ...

Akebia Therapeutics Shareholders Approve Merger with Keryx

Akebia Therapeutics, Inc. (Nasdaq:AKBA) today announced that Akebia shareholders voted to approve the share issuance proposal required to complete the merger with Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) at a special meeting of Akebia shareholders held earlier today. More than 95% of the shares voted at the special meeting voted in favor of the share i...

Walgreens Boots Alliance Schedules Fiscal 2019 First Quarter Earnings Announcement for December 20, 2018

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) will release its fiscal 2019 first quarter earnings results at 7 a.m. Eastern time Thursday, December 20, 2018 followed by a one-hour conference call with Walgreens Boots Alliance management beginning at 8:30 a.m. Eastern time. The conference call will be simulcast through the Walgreens Boots Alliance i...

Monday 10th December 2018

KOKUYO's "360° Gliding Chair ing" Wins FRAME Awards ORGATEC 2018 in Two Categories

KOKUYO starts European expansion auspiciously with the good designed and health conscious office chair. KOKUYO Co., Ltd. (TOKYO:7984), a leading provider of office design and furniture in Japan, won FRAME Awards for "360º Gliding Chair ing" in two categories at ORGATEC 2018, “Trade Fair Sta

Friday 7th December 2018

Most Popular NEJM Group Feature This Week: Editing Human Embryos with CRISPR — A Perspective from an HIV Specialist

Here's the most clicked-on item we featured from NEJM Group this week, in case you missed it the first time around: Last week, scientists...

Precisely fitting bone implants from the printer

Cancerous tumors, infections or bad fractures can make it necessary to surgically remove bones and insert implants in their place. In collaboration with European partners, Fraunhofer researchers have now developed a technique with which bone implants that are precisely fitting, stable and variable i...

Thursday 6th December 2018

Robert Livingston Appointed to Board of Directors of Amphenol Corporation

Amphenol Corporation (NYSE:APH) today announced that Robert A. Livingston, former President and Chief Executive Officer of Dover Corporation (NYSE: DOV), has been appointed to Amphenol’s board of directors. Prior to his retirement in April 2018, Mr. Livingston spent 35 years with the Dover Corporation, including most recently as its Preside...

Tuesday 4th December 2018

Questionmark Founder, John Kleeman, Appointed to Board of Directors for the Association of Test Publishers

Questionmark, global provider of assessment technologies, today announced that John Kleeman, Questionmark Founder and Executive Director, has been elected to the Association of Test Publishers (ATP) Board of Directors. John will serve a two-year term of office for the leading international non-profit organization representing providers of tests and assessm...

Monday 3rd December 2018

Sensors Provide Gentle Lung Treatment for Preemies

NewsResearchers are working to develop a system that would allow drugs to be administered as aerosols in an efficient and breath-triggered manner.

Innovative Color Sensors are Cheaper to Manufacture

NewsTheir extremely slim design makes the sensors suitable for a wide range of applications, such as in mobile devices or color-adjustable LED lamps.C

FDA Authorized Cantrell Drug Company Offers Significant Cost Savings for Sterile Injectable Drugs

James L. McCarley, Jr., Pharm.D. Chairman and CEO of Cantrell Drug Company, https://cantrelldrug.com, a 503B Registered Outsourcing Facility, announced that his Company is seeking to contract with a hospital group, purchasing organization or other pharmaceutical manufacturer to make one or more sterile injectable drugs that will provide significant cost sa...

Friday 30th November 2018

Most Popular NEJM Group Feature This Week: Headache & Nausea Interactive Case

Here's the most clicked-on item we featured from NEJM Group this week, in case you missed it the first time around: NEJM Primary Care...

Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending Akebia Shareholders Vote “FOR” Proposed Merger with Keryx

Akebia Urges Shareholders to Vote “FOR” the Merger-Related Shareholder Proposals Today Akebia Therapeutics, Inc. (Nasdaq:AKBA) (“Akebia” or the “Company”) today announced that leading independent proxy advisory firm, Glass Lewis & Co. (“Glass Lewis”), joins Institutional Shareholder Services (“ISS”) in recommending that Akebia s...

PSNC says pharmacists should be able to substitute drugs to ease Brexit supply pressures

Pharmacy negotiators have suggested that community pharmacists should be able to automatically substitute an alternative medicine if they cannot dispense the prescribed item, as a way to help deal with any possible drugs shortages post-Brexit.

Thursday 29th November 2018

Leading Independent Proxy Advisory Firm ISS Recommends Akebia Shareholders Vote “FOR” Proposed Merger with Keryx

Akebia Urges Shareholders to Vote “FOR” the Merger-Related Shareholder Proposals Today Akebia Therapeutics, Inc. (Nasdaq:AKBA) (“Akebia” or the “Company”) today announced that leading independent proxy advisory firm, Institutional Shareholder Services (“ISS”), recommends that Akebia shareholders vote “FOR” the shareholder proposals ...

Probiodrug AG Reports Third Quarter 2018 Business Update

Probiodrug / Probiodrug AG Reports Third Quarter 2018 Business Update . Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement. Probiodrug AG Reports Third Quarter 2018 Business Update HALLE (SAALE), Germany, 29 November 2018 - Probiodrug AG (Euronext Amsterdam: PBD), a clinical stage biopharmaceutical company d...

Wednesday 28th November 2018

ProAssurance Announces Special and Regular Dividends

The ProAssurance Corporation (NYSE: PRA) Board of Directors today declared a special dividend of $0.50 per share and a regular dividend of $0.31 per share. Both will be paid on January 9, 2019 to shareholders who own our stock as of December 21, 2018. “The special dividend declared today affirms our ongoing commitment to manage our capital effec...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks